Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Authors not listed
University of Bologna · 2009
Abstract
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
After this induction phase, the CR, PR and SD will continue Lenalidomide with the same schedule for other 8 months.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Anonymous. (2009). Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL). <em>University of Bologna</em>. https://clinicaltrials.gov/study/NCT00968331
Vancouver
Anonymous. Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL). University of Bologna. 2009.
BibTeX
@misc{anon2009Studyo,
title = {Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)},
author = {Anonymous},
journal = {University of Bologna},
year = {2009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Sun Yat-sen University 2025
Open access · US-GOV
A Phase II Study of Serplulimab, Chidamide, and Rituximab Followed by R-CHOP in Newly Diagnosed Elderly Patients With MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
University of Aarhus 2003
Open access · US-GOV
A Prospective Multicenter Phase II Study of MabThera (Rituximab) Plus 2 Weekly CHOP Followed by Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma
Ruijin Hospital 2020
Open access · US-GOV
The Efficacy and Safety of Zanubrutinib, Lenalidomide and Rituximab (ZR2) Regimen in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Lymphoma Study Association 2003
Open access · US-GOV
Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab
Jiangsu Province Centers for Disease Control and Prevention 2020
Open access · US-GOV
Safety and Immunogenicity of a Recombinant COVID-19 Vaccine (CHO Cell) in Healthy Population Aged 18 Years and Older: A Phase I Study
The Lymphoma Academic Research Organisation 2011
Open access · US-GOV